Akari Therapeutics Strengthens Board with Two Senior Industry Appointments

Akari Therapeutics (NASDAQ:AKTX) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, is pleased to announce the appointment of Michael Grissinger and Dr. Peter Feldschreiber to the Company’s Board of Directors with immediate effect.
As quoted in the press release:

Mr. Grissinger spent 22 years at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He has led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger brings to Akari Therapeutics extensive experience in business and corporate development, finance, marketing and strategic planning in the pharmaceutical industry.

Click here to read the full press release.